Curi Bio Inc., a Seattle, WA-based developer of human stem cell-based platforms for drug discovery, held the second closing of a $10m Series A financing.
New investors UTC Investment and DS Asset Management joined current investor and Series A lead Dynamk Capital.
The company intends to use the funds to scale its existing business and accelerate the development of its engineered tissue analysis platforms, including its Mantarray™ platform.
Led by Michael Cho, JD, CEO, Curi Bio provides a preclinical discovery platform that combines human stem cells, systems, and data to accelerate the discovery of new medicines. The Curi Engine is a bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and A.I./M.L.-enabled phenotypic screening data. Its suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.
The core technologies and products include:
- NanoSurface™ Plates for structural maturation,
- Cytostretcher™ cell-stretching instruments, and
- the Mantarray platform for contractility analysis.